Research location

Viladecans

Spain

Published trials8
Site observations8
Linked trials published8
Page1 / 1
Advertisement

Research activity in Viladecans

Spain

CureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Viladecans

8 linked trials · page 1 of 1
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic NephropathyNCT02065791 · 2014-02-17 · 1 site observation
COMPLETED
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusNCT01989754 · 2014-01-16 · 1 site observation
COMPLETED
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart FailureNCT01877915 · 2013-09-10 · 1 site observation
COMPLETED
CANVAS - CANagliflozin cardioVascular Assessment StudyNCT01032629 · 2009-12-09 · 1 site observation
COMPLETED
Treatment of Hypertension in Primary Care in SpainNCT00868881 · 2009-03-01 · 1 site observation
COMPLETED
European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT00722267 · 2008-07-01 · 1 site observation
COMPLETED
Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in AdultsNCT00385593 · 2006-09-01 · 1 site observation
TERMINATED
Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid ArthritisNCT01078571 · 2006-05-01 · 1 site observation
COMPLETED
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.